Skip to main content

Table 1 Patients’ clinicopathological information

From: NEK7 promotes gastric cancer progression as a cell proliferation regulator

Characters NEK7-high NEK7-low P-value
Status    
 Alive 103 125  
 Dead 85 62 0.022
Age   
 Mean (SD) 65.7 (10.3) 65.9 (11.1)
 Median [MIN, MAX] 67 [35, 90] 67.5 [39, 90] 0.856
Gender    
 Female 71 63  
 Male 117 124 0.474
Race    
 Asian 28 46  
 Black 6 5  
 White 130 108  
 Islander   1 0.04
pT_stage    
 T1 1 4  
 T1b 2 10  
 T2 22 36  
 T2a 6 3  
 T2b 6 7  
 T3 78 90  
 T4 18 12  
 T4a 33 13  
 T4b 14 10  
 TX 8   
 T1a   2 0.003
pN_stage    
 N0 50 61  
 N1 44 53  
 N2 42 33  
 N3 12 14  
 N3a 26 16  
 N3b 1 5  
 NX 12 4 0.058
pM_stage    
 M0 165 165  
 M1 12 13  
 MX 11 9 0.888
pTNM_stage    
 IA 3 11  
 IB 19 18  
 II 12 15  
 IIA 11 24  
 IIB 27 22  
 IIIA 34 26  
 IIIB 24 28  
 IIIC 24 11  
 IV 19 19  
 I   2  
 III   3 0.036
Grade    
 G1 5 5  
 G2 56 81  
 G3 120 99  
 GX 7 2 0.025
New_tumor_event_type    
 Metastasis 31 23  
 Metastasis: recurrence 3 1  
 Primary 2 1  
 Recurrence 17 12  
 Recurrence: primary   1 0.907
Radiation_therapy    
 Non-radiation 61 84  
 Radiation 25 19 0.122
History_of_neoadjuvant_treatment    
 No neoadjuvant 188 187  
Therapy_type    
 Ancillary: chemotherapy 19 13  
 Chemotherapy 63 65  
 Chemotherapy: other. Specify in notes 1   
 Chemotherapy:   1  
 Chemotherapy: targeted molecular therapy   1 0.406